Skip to main content
Top
Published in: American Journal of Clinical Dermatology 2/2000

01-03-2000 | Review Article

Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs

Pathogenesis, Prevalence, and Management

Authors: Dr Winnie Yeo, Philip J. Johnson

Published in: American Journal of Clinical Dermatology | Issue 2/2000

Login to get access

Abstract

Radiation-recall dermatitis is the occurrence, with subsequent administration of cytotoxic chemotherapy, of an acute inflammatory toxicity in a previously quiescent radiation field. It may occur from days to weeks, and sometimes years, after the radiation therapy. The precise mechanism is unknown. One hypothesis suggests that the initial radiation therapy leads to a depletion of tissue stem cells within the irradiated field and that subsequent cytotoxic chemotherapy exposure causes a ‘remembered’ reaction among the remaining surviving cells. An alternative proposition suggests that radiation induces heritable mutations within surviving cells, which then produce a subgroup of defective stem cells that are unable to tolerate the second insult of chemotherapy. Recently, ataxia telangiectasia gene mutation and protein kinase deficiency have been associated with patients who have increased susceptibility to severe radiation-induced skin toxicity.
Most of the lesions will heal with supportive treatment. Although some reports have noted that radiation-recall dermatitis recurred with subsequent continued administration of the same chemotherapeutic agent, such experience is not universal. At present, a decision as to whether the same chemotherapeutic agent can be continued will usually be determined by the severity of the initial reaction, the chemoresponsiveness of the tumor to this particular agent, the individual patient’s wishes, and a clinical judgment that takes into account the availability of alternative therapy.
Literature
1.
go back to reference Eifel P.J., McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin’s lymphoma of Waldeyer’s ring [letter]. Int J Radiat Oncol Biol Phys 1989; 17: 907–908PubMedCrossRef Eifel P.J., McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin’s lymphoma of Waldeyer’s ring [letter]. Int J Radiat Oncol Biol Phys 1989; 17: 907–908PubMedCrossRef
2.
go back to reference Mcinerney D.P., Bullimore J. Reactivation of radiation pneumonitis by adriamycin.Br J Radiol 1977; 50: 224–227CrossRef Mcinerney D.P., Bullimore J. Reactivation of radiation pneumonitis by adriamycin.Br J Radiol 1977; 50: 224–227CrossRef
3.
go back to reference Cassady J.R., Richter M.T., Piro A.J., et al. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946–949PubMedCrossRef Cassady J.R., Richter M.T., Piro A.J., et al. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946–949PubMedCrossRef
4.
go back to reference Kellie S.J., Plowman P.N., Malpas J.S. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; I (8542): 1149–1150CrossRef Kellie S.J., Plowman P.N., Malpas J.S. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; I (8542): 1149–1150CrossRef
5.
go back to reference Donaldson S.S., Glick J.M., Wilbur J.R. Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 1974; 81: 407–408PubMed Donaldson S.S., Glick J.M., Wilbur J.R. Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 1974; 81: 407–408PubMed
6.
go back to reference Redpath J.L., Cloman M. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet. Int J Radiat Oncol Biol Phys 1979; 5: 483–486PubMedCrossRef Redpath J.L., Cloman M. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet. Int J Radiat Oncol Biol Phys 1979; 5: 483–486PubMedCrossRef
7.
go back to reference D’Angio G.J., Farber S., Maddock C.L. Potentiation of X-ray effects by actinomycin D. Radiology 1959; 73: 175–177PubMed D’Angio G.J., Farber S., Maddock C.L. Potentiation of X-ray effects by actinomycin D. Radiology 1959; 73: 175–177PubMed
8.
go back to reference Pui C.H., de Graaf S.S.N., Dow L.W., et al. Phase 1 clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1998; 48: 5348–5352 Pui C.H., de Graaf S.S.N., Dow L.W., et al. Phase 1 clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1998; 48: 5348–5352
9.
go back to reference Steizer K.J., Griffin T.W., Koh W.J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome.Cancer 1993; 71: 1322–1325CrossRef Steizer K.J., Griffin T.W., Koh W.J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome.Cancer 1993; 71: 1322–1325CrossRef
10.
go back to reference Von Essen C.F., Kilgerman M.M. Calbresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology 1963; 81: 1018–1027 Von Essen C.F., Kilgerman M.M. Calbresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology 1963; 81: 1018–1027
11.
go back to reference Nemechek P.M., Corder M.C. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related with Acquired Immune Deficiency Syndrome. Cancer 1992; 70: 1605–1606PubMedCrossRef Nemechek P.M., Corder M.C. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related with Acquired Immune Deficiency Syndrome. Cancer 1992; 70: 1605–1606PubMedCrossRef
12.
go back to reference Sears M.E. Erythema in areas of previous irradiation in patients treated with hydroxyurea (NSC-32065). Cancer Chemother Rep 1964; 40: 31–32PubMed Sears M.E. Erythema in areas of previous irradiation in patients treated with hydroxyurea (NSC-32065). Cancer Chemother Rep 1964; 40: 31–32PubMed
13.
go back to reference Jolivet J., Landry L., Pinard M.F., et al. A Phase 1 study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172PubMedCrossRef Jolivet J., Landry L., Pinard M.F., et al. A Phase 1 study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172PubMedCrossRef
14.
go back to reference Fontana J.A. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224–225PubMed Fontana J.A. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224–225PubMed
15.
go back to reference Phillips K.A., Urch M., Bishop J.F. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305PubMed Phillips K.A., Urch M., Bishop J.F. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305PubMed
16.
go back to reference Shenkier T., Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol1994; 12: 439 Shenkier T., Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol1994; 12: 439
17.
go back to reference Yeo W., Leung S.F., Johnson P.J. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33 (4): 698–699PubMedCrossRef Yeo W., Leung S.F., Johnson P.J. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33 (4): 698–699PubMedCrossRef
18.
go back to reference Philips T.L., Fu K.K. Quantification of combined radiation therapy and chemotherapy affects on critical normal tissues. Cancer 1976; 37: 1186–1200CrossRef Philips T.L., Fu K.K. Quantification of combined radiation therapy and chemotherapy affects on critical normal tissues. Cancer 1976; 37: 1186–1200CrossRef
19.
go back to reference Fu K.K. Normal tissue effects of combined radiotherapy and chemotherapy for head and neck cancer. Front Radiat Ther Oncol 1979; 13: 113–132 Fu K.K. Normal tissue effects of combined radiotherapy and chemotherapy for head and neck cancer. Front Radiat Ther Oncol 1979; 13: 113–132
20.
go back to reference Cantril S.T. Audience interaction. Front Radiat Ther Oncol 1979; 13: 145–146 Cantril S.T. Audience interaction. Front Radiat Ther Oncol 1979; 13: 145–146
21.
go back to reference Danjoux C.E. Delayed complications following combination of radiation and chemotherapy.Int J Radiat Oncol Biol Phys 1979; 5: 441–443PubMedCrossRef Danjoux C.E. Delayed complications following combination of radiation and chemotherapy.Int J Radiat Oncol Biol Phys 1979; 5: 441–443PubMedCrossRef
22.
go back to reference Philips T.L., Wharam M.D., Margolis L.W. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975; 34: 1678–1684CrossRef Philips T.L., Wharam M.D., Margolis L.W. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975; 34: 1678–1684CrossRef
23.
go back to reference Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int J Radiat Oncol Biol Phys 1994; 30: 997–1002PubMedCrossRef Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int J Radiat Oncol Biol Phys 1994; 30: 997–1002PubMedCrossRef
24.
go back to reference West C.M., Elyan S.A., Berry P., et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients and individuals with ataxiatelangiectasia (A-T) and A-T heterozygotes. Int J Radiat Oncol Biol Phys 1995; 68: 197–203 West C.M., Elyan S.A., Berry P., et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients and individuals with ataxiatelangiectasia (A-T) and A-T heterozygotes. Int J Radiat Oncol Biol Phys 1995; 68: 197–203
25.
go back to reference Jongmans W., Artuso M., Vuillaume M., et al. The role of ataxia-telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionizing radiation. Oncogene 1996; 13: 1133–1138PubMed Jongmans W., Artuso M., Vuillaume M., et al. The role of ataxia-telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionizing radiation. Oncogene 1996; 13: 1133–1138PubMed
26.
go back to reference Opptiz U., Bernthaler U., Schindler D., et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999: 44: 981–988CrossRef Opptiz U., Bernthaler U., Schindler D., et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999: 44: 981–988CrossRef
27.
go back to reference Tan C.T.C., Dargeon H.W., Burchenal J.H. The effect of actinomycin D on cancer in childhood. Pediatric 1959; 24: 544–561 Tan C.T.C., Dargeon H.W., Burchenal J.H. The effect of actinomycin D on cancer in childhood. Pediatric 1959; 24: 544–561
28.
go back to reference Seymour C.B., Mothersill Q., Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol 1986; 50: 167–179CrossRef Seymour C.B., Mothersill Q., Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol 1986; 50: 167–179CrossRef
29.
go back to reference Hellman S., Botnick L.E. Skin cell depletion. an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181–184PubMedCrossRef Hellman S., Botnick L.E. Skin cell depletion. an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181–184PubMedCrossRef
30.
go back to reference Tsichler R.B., Schiff P.B., Geard C.R., et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613–617CrossRef Tsichler R.B., Schiff P.B., Geard C.R., et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613–617CrossRef
31.
go back to reference Kitani H., Kosaka T., FukMara T., et al. The ‘recall effect’ in radiotherapy: is subeffective, reparable damage responsible? Int J Radiat Oncol Biol Phys 1990; 18: 689–695PubMedCrossRef Kitani H., Kosaka T., FukMara T., et al. The ‘recall effect’ in radiotherapy: is subeffective, reparable damage responsible? Int J Radiat Oncol Biol Phys 1990; 18: 689–695PubMedCrossRef
Metadata
Title
Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs
Pathogenesis, Prevalence, and Management
Authors
Dr Winnie Yeo
Philip J. Johnson
Publication date
01-03-2000
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2000
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200001020-00006

Other articles of this Issue 2/2000

American Journal of Clinical Dermatology 2/2000 Go to the issue

Adis New Drug Profile

Topical Aminolevulinic Acid HCl

Adis New Drug Profile

Topical Aminolevulinic Acid HCL